Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose versus low-dose cytarabine-based therapy followed by interferon alfa-2a maintenance in newly diagnosed chronic myeloid leukemia
NL-OMON27157Phase 3Active, not recruiting
- Sponsor
- HOVON
- Start
- Jan 1998
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cytarabine, interferon alfa-2a, idarubicin and hydroxyurea in chronic myelogenous leukemia (CML) (3 arms), sponsored by HOVON. Primary endpoint: Event-free survival. Started Jan 1998; status: active, not recruiting.
02
Drugs
cytarabineinterferon alfa-2aidarubicinhydroxyurea
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NL-OMON27157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27157.